M 041
Alternative Names: M-041; NAGLUM6PLatest Information Update: 12 Apr 2023
At a glance
- Originator M6P Therapeutics
- Class Enzymes; Recombinant proteins
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Mucopolysaccharidosis III
Most Recent Events
- 12 Apr 2023 Discontinued - Preclinical for Mucopolysaccharidosis III in USA (unspecified route) (M6P Therapeutics pipeline, April 2023)
- 07 Feb 2022 Pharmacodynamics data from preclinical trial presented at the 18th Annual WORLDSymposium™ (Annual WORLDSymposium-2022)
- 04 Feb 2021 M 041 is available for licensing as of 04 Feb 2021.